Hutchmed (China) (HKG:0013) agreed to dispose of its 35% equity in Shanghai Hutchison Pharmaceuticals or SHPL to two entities under GP Health Service Capital for 3.48 billion yuan, according to a Hong Kong Stock Exchange filing on Monday.
Shanghai GP Zhicheng Private Equity Investment Fund Partnership (Limited Partnership) will acquire 25.1% and Shanghai GP Zhibaihe Enterprise Management Partnership (Limited Partnership) will buy 9.9% of SHPL for 2.50 billion yuan and 982.6 million yuan, respectively.
Shanghai Pharmaceuticals (HKG:2607, SHA:601607) agreed in January to takeover 10% of SHPL, the pharmaceutical company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.